Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Glossary Glossary
The Body Covers: The 5th Conference on Retroviruses and Opportunistic Infections
The Impact of HAART on Rates and Types of Hospitalizations

February 2, 1998

Poster session abstracts 179-184, 198, 205-206, 257

The impact of HAART on rates and types of hospitalizations was addressed by numerous groups in the US, Canada and Europe. Viewed together, these studies reported a 50% reduction in hospitalization rates and in specific OI incidences. Some studies also reported a sharp reduction in in-hospital mortality as well.

Forrest (#179) reporting on experience in Vancouver, found that between 1994 and 1996, rates per 1000 patient days decreased for KS (from 16 to 2), PCP (from 28 to 8) and other OIs (from 60 to 8). The decrease was seen for both prophylaxis preventable (e.g., PCP) and non-preventable (e.g., KS, wasting) conditions.

The UCSF experience was reported by Holtzer (#183). They reported similar decreases between 1994 and 1997 in a well-defined group of patients: PCP incidence was down 71%, CMV incidence was down 94%, and MAC incidence was down 84%.

A decline in mortality was noted by several researchers (posters #180, #184, #198). For example, the HIV Outpatient Study (HOPS), led by the CDC and investigators in Chicago (#198) described a decrease in mortality among approximately 1700 prospectively followed patients, from 29.5 deaths per 100 patient years per quarter in 1995 to 8.8 deaths per 100 patient years per quarter in 1997.

Lower rates of bacterial pneumonia were reported by several investigators (posters #182, #184, #205). For example, Paul (#205) and colleagues noted that the incidence of bacterial pneumonia (PCP), the most common reason for hospitalization among AIDS patients, decreased by 50% from 1995 to 1997 at New York Hospital.

The possible explanation for this drop was shown by work from Morris and colleagues (#170). They studied B-cell function in patients receiving HAART and found a decrease in B-cell hyperactivity, with a significant return toward normal function. Thus, the decrease in rates of PCP which exploits B-cell rather than T-cell dysfunction, may be related to this effect.

See Also
More on the Economics of HIV Care



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement